| 12.3 -0.2 (-1.6%) | 10-12 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 15.23 |
1-year : | 16.24 |
| Resists | First : | 13.04 |
Second : | 13.9 |
| Pivot price | 12.43  |
|||
| Supports | First : | 11.64 | Second : | 9.68 |
| MAs | MA(5) : | 12.28 |
MA(20) : | 12.41 |
| MA(100) : | 13.07 |
MA(250) : | 13.25 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 36.4 |
D(3) : | 35.2 |
| RSI | RSI(14): 45.4 |
|||
| 52-week | High : | 17.14 | Low : | 10.19 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ENTA ] has closed above bottom band by 40.8%. Bollinger Bands are 37.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 12.66 - 12.73 | 12.73 - 12.78 |
| Low: | 12.01 - 12.09 | 12.09 - 12.16 |
| Close: | 12.18 - 12.31 | 12.31 - 12.41 |
Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focused on addressing pathogens such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and the hepatitis B virus (HBV). The company also holds a strategic partnership and licensing agreement with Abbott Laboratories. This collaboration involves the joint identification, development, and market introduction of specific HCV NS3 and NS3/4A protease inhibitor compounds, including known agents like paritaprevir and glecaprevir, which are utilized in the management of chronic hepatitis C virus. Founded in 1995, Enanta Pharmaceuticals, Inc. operates from its principal office located in Watertown, Massachusetts.
Thu, 08 Oct 2026
Wall Street Zen upgrades Enanta Pharmaceuticals stock to Hold - ad-hoc-news.de
Wed, 07 Oct 2026
Enanta Pharmaceuticals (ENTA) Climbs 2.14% as Shares Test Upper Range - Put Wall - https://www.dars.gov.et/
Sat, 03 Oct 2026
Enanta Pharmaceuticals (ENTA) Ticks Higher to $12.96 as Shares Press Toward Resistance - TWAP Entry - https://www.siam.in/
Sat, 26 Sep 2026
How Enanta Pharmaceuticals Inc. (ENTA) Affects Rotational Strategy Timing - Stock Traders Daily
Tue, 11 Aug 2026
Enanta Pharmaceuticals (ENTA) Stock Faces Revenue Slip And Wider Losses - Simply Wall Street
Mon, 10 Aug 2026
Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 29 (M) |
| Shares Float | 23 (M) |
| Held by Insiders | 4.6 (%) |
| Held by Institutions | 94.3 (%) |
| Shares Short | 2,550 (K) |
| Shares Short P.Month | 2,620 (K) |
| EPS | -2.43 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.47 |
| Profit Margin | -96.9 % |
| Operating Margin | -120.1 % |
| Return on Assets (ttm) | -12.3 % |
| Return on Equity (ttm) | -70.2 % |
| Qtrly Rev. Growth | -21.7 % |
| Gross Profit (p.s.) | 2.24 |
| Sales Per Share | 2.24 |
| EBITDA (p.s.) | -1.85 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -35 (M) |
| Levered Free Cash Flow | -23 (M) |
| PE Ratio | -5.09 |
| PEG Ratio | 0 |
| Price to Book value | 3.54 |
| Price to Sales | 5.49 |
| Price to Cash Flow | -10.15 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|